Oral etoposide in elderly patients with advanced non small cell lung cancer: A clinical and pharmacological study

Roberto Sorio, G. Toffoli, D. Crivellari, A. Bearz, G. Corona, A. M. Colussi, M. Libra, R. Talamini, A. Veronesi

Research output: Contribution to journalArticlepeer-review

Abstract

Seventeen elderly patients with advanced progressive non small cell lung cancer (NSCLC) were treated with oral etoposide at the daily dose of 100 mg for 14 days every 3-4 weeks with pharmacokinetic monitoring. One partial response and 6 stabilizations were documented with a median overall duration of 13 weeks (range 8-32). The median survival was 24 weeks with an apparent advantage for non-progressive patients (40 weeks vs. 18 weeks). The treatment was well tolerated especially by those patients without concomitant illness, suggesting the crucial role of a careful selection of the geriatric population. Toxicity was not related to the etoposide plasma level, but was clearly dependent on comorbidity. A geriatric assessment rather than chronological age therefore appears to be more reliable in the selection of elderly patients for clinical trials. The easy self-management, favorable toxicity profile and synergy with other compounds makes oral etoposide suitable for further clinical- pharmacological studies in elderly patients.

Original languageEnglish
Pages (from-to)188-191
Number of pages4
JournalJournal of Chemotherapy
Volume18
Issue number2
Publication statusPublished - Apr 2006

Keywords

  • Elderly
  • Etoposide
  • Non-small cell lung cancer
  • Pharmacokinetics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Oral etoposide in elderly patients with advanced non small cell lung cancer: A clinical and pharmacological study'. Together they form a unique fingerprint.

Cite this